AVEO Pharmaceuticals, Inc. Restricted Stock AgreementRestricted Stock Agreement • March 30th, 2012 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
AVEO Pharmaceuticals, Inc. (the “Company”) has selected you to receive the restricted stock award described above, which is subject to the provisions of the Company’s 2010 Stock Incentive Plan (the “Plan”) and the terms and conditions contained in this Restricted Stock Agreement. Please confirm your acceptance of this restricted stock award and of the terms and conditions of this Agreement by signing a copy of this Agreement where indicated below.
AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 30th, 2012 • Aveo Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 21st day of December, 2011 by and among AVEO PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), and each of Parent’s Subsidiaries joined thereto (the “Joined Subsidiaries”; the Joined Subsidiaries and Parent are hereinafter referred to collectively as the “Borrower”), and HERCULES TECHNOLOGY II, L.P., a Delaware limited partnership (“Hercules II”), and HERCULES TECHNOLOGY III, L.P., a Delaware limited partnership (“Hercules III”, together with Hercules II collectively referred to as the “Lender”), as acknowledged and agreed by AVEO Securities Corporation, a Massachusetts corporation. Capitalized terms used herein without definition shall have the same meanings given them in the Loan Agreement (as defined below).
AVEO Pharmaceuticals, Inc. 75 Sidney Street Cambridge, MA 02139 www.aveopharma.comAveo Pharmaceuticals Inc • March 30th, 2012 • Pharmaceutical preparations
FIRST AMENDMENT TO CONSENT TO SUBLEASEAveo Pharmaceuticals Inc • March 30th, 2012 • Pharmaceutical preparations
THIS FIRST AMENDMENT TO CONSENT TO SUBLEASE (this “First Amendment”), dated as of September 1, 2011, is made with reference to that certain Sublease Agreement (the “Sublease”) dated as of February 28, 2011, by and between ACCELERON PHARMA, INC. a Delaware corporation with an address of 128 Sidney Street, Cambridge, Massachusetts 02139 (“Sublandlord”), and AVEO PHARMACEUTICALS, INC., a Delaware corporation with an address of 75 Sidney Street, Cambridge, MA 02139 (“Subtenant”), and is entered into by and among Sublandlord, Subtenant and MASSACHUSETTS INSTITUTE OF TECHNOLOGY, a Massachusetts charitable corporation with an address c/o MIT Investment Management Company, 238 Main Street, Suite 200, Cambridge, MA 02142 (“Prime Landlord”), with reference to the following facts:
